Tongxinluo ameliorates renal structure and function by regulating mir-21-induced epithelial-to-mesenchymal transition in diabetic nephropathy

American Journal of Physiology - Renal Physiology

Volumn 306, Issue 5, 2014, Pages

  Wang, Jin Yang ^a,b   Gao, Yan Bin ^a   Zhang, Na ^a   Zou, Da Wei ^a   Xu, Li Ping ^a   Zhu, Zhi Yao ^a   Li, Jiao Yang ^a   Zhou, Sheng Nan ^a   Cui, Fang Qiang ^a   Zeng, Xiang Jun ^a   Geng, Jian Guo ^a   Yang, Jin Kui ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Epithelial to mesenchymal transition (EMT); MicroRNA; Tongxinluo (TXL)

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA ACTIN; COLLAGEN TYPE 4; FIBRONECTIN; HERBACEOUS AGENT; MICRORNA 21; SMAD3 PROTEIN; SMAD7 PROTEIN; TONGXINLUO; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; UVOMORULIN; CADHERIN; MICRORNA; MIRN21 MICRORNA, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DOWN REGULATION; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; GENE CONTROL; GENE OVEREXPRESSION; GLOMERULUS BASEMENT MEMBRANE; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; KIDNEY FUNCTION; KIDNEY PARENCHYMA; KIDNEY STRUCTURE; KIDNEY TUBULE; MALE; MOUSE; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; DRUG EFFECT; EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT); EPITHELIUM CELL; GENETICS; METABOLISM; TONGXINLUO (TXL);

DIABETIC NEPHROPATHY; EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT); MICRORNA; TONGXINLUO (TXL);

CADHERINS; CELL DIFFERENTIATION; CELL LINE; DIABETIC NEPHROPATHIES; DRUGS, CHINESE HERBAL; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICRORNAS;

EID: 84899144933     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00528.2013     Document Type: Article

References (46)

1. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, Bar-Eli M, Dinney C. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 15: 5060-5072, 2009.
2. Bronnum H, Andersen DC, Schneider M, Sandberg MB, Eskildsen T, Nielsen SB, Kalluri R, Sheikh SP. miR-21 promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving Programmed Cell Death 4 and Sprouty-1. PLoS One 8: e56280, 2013.
3. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature 454: 56-61, 2008.
4. Duan SB, Liu GL, Wang YH, Zhang JJ. Epithelial-to-mesenchymal transdifferentiation of renal tubular epithelial cell mediated by oxidative stress and intervention effect of probucol in diabetic nephropathy rats. Ren Fail 34: 1244-1251, 2012.
5. Guan QG Zeng DY, Sun XZ. [Inhibitory effect and acting mechanism of Tongxinluo on IL-1beta-mediated coronary intimal hyperplasia and 5-hydroxytryptamine- induced coronary vasospasm in small swine]. Zhongguo Zhong Xi Yi Jie He Za Zhi 28: 627-631, 2008.
6. Han M, Liu M, Wang Y, Mo Z, Bi X, Liu Z, Fan Y, Chen X, Wu C. Re-expression of miR-21 contributes to migration and invasion by inducing epithelial-mesenchymal transition consistent with cancer stem cell characteristics in MCF-7 cells. Mol Cell Biochem 363: 427-436, 2012.
7. Han M, Wang Y, Liu M, Bi X, Bao J, Zeng N, Zhu Z, Mo Z, Wu C, Chen X. MiR-21 regulates epithelial-mesenchymal transition phenotype and hypoxia-inducible factor-1alpha expression in third-sphere forming breast cancer stem cell-like cells. Cancer Sci 103: 1058-1064, 2012.
8. Hills CE, Squires PE. The role of TGF-beta and epithelial-to mesenchymal transition in diabetic nephropathy. Cytokine Growth Factor Rev 22: 131-139, 2011.
9. Ito T, Tanimoto M, Yamada K, Kaneko S, Matsumoto M, Obayashi K, Hagiwara S, Murakoshi M, Aoki T, Wakabayashi M, Gohda T, Funabiki K, Maeda K, Horikoshi S, Tomino Y. Glomerular changes in the KK-Ay/Ta mouse: a possible model for human type 2 diabetic nephropathy. Nephrology (Carlton) 11: 29-35, 2006.
10. Kong Q, Yang XC, Liu XL. [Effects of tongxinluo on the myocardial inflammatory reaction and expression of tumor necrosis factor-alpha in rats with myocardial infarction]. Zhongguo Zhong Xi Yi Jie He Za Zhi 26: 545-549, 2006.
11. Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH, Thum T. Transforming growth factor-beta-induced endothelial-to-mesenchymal transition is partly mediated by microRNA-21. Arterioscler Thromb Vasc Biol 32: 361-369, 2012.
12. Lan HY. Smad7 as a therapeutic agent for chronic kidney diseases. Front Biosci 13: 4984-4992, 2008.
13. Li J, Wang Y, Luo J, Fu Z, Ying J, Yu Y, Yu W. miR-134 inhibits epithelial to mesenchymal transition by targeting FOXM1 in non-small cell lung cancer cells. FEBS Lett 586: 3761-3765, 2012.
14. Li JH, Zhu HJ, Huang XR, Lai KN, Johnson RJ, Lan HY. Smad7 inhibits fibrotic effect of TGF-beta on renal tubular epithelial cells by blocking Smad2 activation. J Am Soc Nephrol 13: 1464-1472, 2002.
15. Li XD, Yang YJ, Geng YJ, Jin C, Hu FH, Zhao JL, Zhang HT, Cheng YT, Qian HY, Wang LL, Zhang BJ, Wu YL. Tongxinluo reduces myocardial no-reflow and ischemia-reperfusion injury by stimulating the phosphorylation of eNOS via the PKA pathway. Am J Physiol Heart Circ Physiol 299: H1255-H1261, 2010.
16. Liang JQ, Wu K, Jia ZH, Liu C, Ding J, Huang SN, Yin PP, Wu XC, Wei C, Wu YL, Wang HY. Chinese medicine tongxinluo modulates vascular endothelial function by inducing eNOS expression via the PI- 3K/Akt/HIF-dependent signaling pathway. J Ethnopharmacol 133: 517-523, 2011.
17. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 15: 1-12, 2004.
18. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J Am Soc Nephrol 21: 212-222, 2010.
19. Mason RM, Wahab NA. Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14: 1358-1373, 2003.
20. Nishi S, Ueno M, Hisaki S, Iino N, Iguchi S, Oyama Y, Imai N, Arakawa M, Gejyo F. Ultrastructural characteristics of diabetic nephropathy. Med Electron Microsc 33: 65-73, 2000.
21. Nuovo GJ. In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. Methods 44: 39-46, 2008.
22. Osterby R. Morphometric studies of the peripheral glomerular basement membrane. II. Topography of the initial lesions. Diabetologia 9: 108-114, 1973.
23. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
24. Reidy K, Susztak K. Epithelial-mesenchymal transition and podocyte loss in diabetic kidney disease. Am J Kidney Dis 54: 590-593, 2009.
25. Rychlik I, Miltenberger-Miltenyi G, Ritz E. The drama of the continuous increase in end-stage renal failure in patients with type II diabetes mellitus. Nephrol Dial Transplant 13, Suppl 8: 6-10, 1998.
26. Saika S, Ikeda K, Yamanaka O, Sato M, Muragaki Y, Ohnishi Y, Ooshima A, Nakajima Y, Namikawa K, Kiyama H, Flanders KC, Roberts AB. Transient adenoviral gene transfer of Smad7 prevents injury-induced epithelial-mesenchymal transition of lens epithelium in mice. Lab Invest 84: 1259-1270, 2004.
27. Schmittgen TD, Lee EJ, Jiang J, Sarkar A, Yang L, Elton TS, Chen C. Real-time PCR quantification of precursor and mature microRNA. Methods 44: 31-38, 2008.
28. Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 93: 583-593, 2012.
29. Tu Q, Qin J, Dong H, Lu F, Guan W. Effects of Panax notoginoside on the expression of TGF-beta1 and Smad-7 in renal tissues of diabetic rats. J Huazhong Univ Sci Technolog Med Sci 31: 190-193, 2011.
30. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106: 672-678, 2002.
31. Wang HJ, Huang YW, Sun J. [Effect of tongxinluo capsule on function of vascular endothelium in patients with unstable angina pectoris]. Zhongguo Zhong Xi Yi Jie He Za Zhi 23: 587-589, 2003.
32. Wang J, Gao Y, Ma M, Li M, Zou D, Yang J, Zhu Z, Zhao X. Effect of miR-21 on renal fibrosis by regulating MMP-9 and TIMP1 in kk-ay diabetic nephropathy mice. Cell Biochem Biophys 67: 537-546, 2013.
33. Wang Y, Li W, Zang X, Chen N, Liu T, Tsonis PA, Huang Y. MicroRNA-204-5p regulates epithelial-to-mesenchymal transition during human posterior capsule opacification by targeting SMAD4. Invest Ophthalmol Vis Sci 54: 323-332, 2013.
34. Wang Y, Qian P, Liu P, Wei L, Cao M, Zhou L, Zhou D, Lin ZX. Effects of Panax notoginseng flower extract on the TGF-beta/Smad signal transduction pathway in heart remodeling of human chymase transgenic mice. Mol Med Rep 5: 1443-1448, 2012.
35. Wu T, Harrison RA, Chen X, Ni J, Zhou L, Qiao J, Wang Q, Wei J, Xin D, Zheng J. Tongxinluo (Tong xin luo or Tong-xin-luo) capsule for unstable angina pectoris. Cochrane Database Syst Rev CD004474, 2006.
36. Xie XS, Liu HC, Yang M, Zuo C, Deng Y, Fan JM. Ginsenoside Rb1, a panoxadiol saponin against oxidative damage and renal interstitial fibrosis in rats with unilateral ureteral obstruction. Chin J Integr Med 15: 133-140, 2009.
37. Xu GC, Gao RL, Wu YL. [Clinical study on tongxinluo capsule in treatment of patients with angina pectoris caused by coronary heart disease]. Zhongguo Zhong Xi Yi Jie He Za Zhi 17: 414-416, 1997.
38. Yokozawa T, Nakagawa T, Wakaki K, Koizumi F. Animal model of diabetic nephropathy. Exp Toxicol Pathol 53: 359-363, 2001.
39. Yuan GQ, Wu YL, Jia ZH. [Experimental study on effect of Tongxinluo on nerve cell apoptosis after cerebral ischemia in middle cerebral arterial obstructive model rats]. Zhongguo Zhong Xi Yi Jie He Za Zhi 27: 720-723, 2007.
40. Zavadil J, Bottinger EP. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24: 5764-5774, 2005.
41. Zeng J, Dou Y, Guo J, Wu X, Dai Y. Paeoniflorin of Paeonia lactiflora prevents renal interstitial fibrosis induced by unilateral ureteral obstruction in mice. Phytomedicine 20: 753-759, 2013.
42. Zhang J, Zhang H, Liu J, Tu X, Zang Y, Zhu J, Chen J, Dong L. miR-30 inhibits TGF-beta1-induced epithelial-to-mesenchymal transition in hepatocyte by targeting Snail1. Biochem Biophys Res Commun 417: 1100-1105, 2012.
43. Zhang L, Liu Y, Lu XT, Wu YL, Zhang C, Ji XP, Wang R, Liu CX, Feng JB, Jiang H, Xu XS, Zhao YX, Zhang Y. Traditional Chinese medication Tongxinluo dose-dependently enhances stability of vulnerable plaques: a comparison with a high-dose simvastatin therapy. Am J Physiol Heart Circ Physiol 297: H2004-H2014, 2009.
44. Zhong X, Chung AC, Chen HY, Dong Y, Meng XM, Li R, Yang W, Hou FF, Lan HY. miR-21 is a key therapeutic target for renal injury in a mouse model of type 2 diabetes. Diabetologia 56: 663-674, 2013.
45. Zhong X, Chung AC, Chen HY, Meng XM, Lan HY. Smad3-mediated upregulation of miR-21 promotes renal fibrosis. J Am Soc Nephrol 22: 1668-1681, 2011.
46. Zhuo Q, Yang X, Wu T, Liu G, Zhou L. Tongxinluo capsule for acute stroke. Cochrane Database Syst Rev CD004584, 2008.